These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost-effectiveness of norovirus vaccination in children in Peru. Mirelman AJ; Ballard SB; Saito M; Kosek MN; Gilman RH Vaccine; 2015 Jun; 33(27):3084-91. PubMed ID: 25980428 [TBL] [Abstract][Full Text] [Related]
3. Epidemiologic challenges in norovirus vaccine development. Hallowell BD; Parashar UD; Hall AJ Hum Vaccin Immunother; 2019; 15(6):1279-1283. PubMed ID: 30481104 [TBL] [Abstract][Full Text] [Related]
4. The potential economic value of a human norovirus vaccine for the United States. Bartsch SM; Lopman BA; Hall AJ; Parashar UD; Lee BY Vaccine; 2012 Nov; 30(49):7097-104. PubMed ID: 23026689 [TBL] [Abstract][Full Text] [Related]
5. Modelling the epidemiological impact of rotavirus vaccination in Germany--a Bayesian approach. Weidemann F; Dehnert M; Koch J; Wichmann O; Höhle M Vaccine; 2014 Sep; 32(40):5250-7. PubMed ID: 25045820 [TBL] [Abstract][Full Text] [Related]
6. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140 [TBL] [Abstract][Full Text] [Related]
7. Duration of immunity to norovirus gastroenteritis. Simmons K; Gambhir M; Leon J; Lopman B Emerg Infect Dis; 2013 Aug; 19(8):1260-7. PubMed ID: 23876612 [TBL] [Abstract][Full Text] [Related]
8. The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control. Lopman BA; Steele D; Kirkwood CD; Parashar UD PLoS Med; 2016 Apr; 13(4):e1001999. PubMed ID: 27115709 [TBL] [Abstract][Full Text] [Related]
9. Norovirus Vaccine: Priorities for Future Research and Development. Esposito S; Principi N Front Immunol; 2020; 11():1383. PubMed ID: 32733458 [TBL] [Abstract][Full Text] [Related]
10. Re-assessing the total burden of norovirus circulating in the United Kingdom population. Harris JP; Iturriza-Gomara M; O'Brien SJ Vaccine; 2017 Feb; 35(6):853-855. PubMed ID: 28094075 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of childhood rotavirus vaccination in Germany. Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052 [TBL] [Abstract][Full Text] [Related]
12. In Depth Breadth Analyses of Human Blockade Responses to Norovirus and Response to Vaccination. Haynes J; Perry V; Benson E; Meeks A; Watts G; Watkins H; Braun R Viruses; 2019 Apr; 11(5):. PubMed ID: 31035476 [TBL] [Abstract][Full Text] [Related]
13. Progress on norovirus vaccine research: public health considerations and future directions. Mattison CP; Cardemil CV; Hall AJ Expert Rev Vaccines; 2018 Sep; 17(9):773-784. PubMed ID: 30092671 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults. Sherwood J; Mendelman PM; Lloyd E; Liu M; Boslego J; Borkowski A; Jackson A; Faix D; Vaccine; 2020 Sep; 38(41):6442-6449. PubMed ID: 32878708 [TBL] [Abstract][Full Text] [Related]
19. Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options. Steele MK; Remais JV; Gambhir M; Glasser JW; Handel A; Parashar UD; Lopman BA Epidemics; 2016 Dec; 17():42-49. PubMed ID: 27821278 [TBL] [Abstract][Full Text] [Related]
20. Global age distribution of pediatric norovirus cases. Shioda K; Kambhampati A; Hall AJ; Lopman BA Vaccine; 2015 Aug; 33(33):4065-8. PubMed ID: 26051514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]